低分子肝素用于急性心肌梗死溶栓后辅助治疗的临床观察

目的 :探讨低分子肝素用于急性心肌梗死溶栓后辅助治疗的疗效与安全性。方法 :6 4例急性心肌梗死患者采用尿激酶溶栓再通后随机分为肝素组 (肝素钙 75 0 0U皮下注射 ,每日 2次 )和低分子肝素组 (低分子肝素 0 .1mL/kg皮下注射 ,每日 2次 ) ,连续 7d。结果 :治疗后两组心肌再梗死、梗死后心绞痛、血管性死亡及出血肝素组均显著高于低分子肝素组 (P <0 .0 5 )。结论 :急性心肌梗死溶栓后使用低分子肝素代替普通肝素作为抗凝剂是安全有效的。

Application of low-molecular weight heparin in assistant treatment after thrombolytic therapy of acute myocardiac infarction

Objectives:In order to study the therapeutic effects and safety of Low-molecular weight heparin(LMWH)in assistant treatment after thrombolytic therapy of acute myocardiac infarction(AMI).Mathods:64 AMI cases after thrombolytic therapy with UK were randomly divited into two groups:Gerneral Hepatin Group(heparin calcium,7500U,twice daily subcutaneously)and LMWH group(LMWH,0.1 mg/kg,twice daily subcutaneously).Both were treated within 7 days.Results:The occurance of re-MI,angina pectoris post-MI,cardiac death and bleeding after treatment in General Heparin Group was much higher than that in LMWH group(P>0.05).Conclusion:It is safe and effectice that LMWH as the anti-coagulation agents insteads of general heparin after thrombolytic therapy of AMI patients.